Teva's Higher-Dose Copaxone Cut MS Relapses in Trial
News | 14 June 2012
Teva, the world's largest maker of generic drugs, is trying to stave off competition for Copaxone, which generated 21 percent of its revenue in 2011. Newer ...
Click on the link to read the full article at BusinessWeek
(This link will open in a new window)
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
